Evotec SE (XSWX:EVT) 5-Year Share Buyback Ratio: -1.20% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:EVT Evotec SE XSWX:EVT
58 GF Score
Price CHF4.63
GF Value CHF8.56
! 4 Warning Signs
View Full Analysis

What is Evotec SE 5-Year Share Buyback Ratio?

Evotec SE XSWX:EVT 58 5-Year Share Buyback Ratio is -1.20 as of Mar. 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 58/100 and a GF Value™ of CHF8.56. The stock has 4 warning signs investors should review. Among 696 Drug Manufacturers companies, Evotec SE ranks better than 57.04% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Evotec SE's current 5-Year Share Buyback Ratio was -1.20%.

XSWX:EVT's 5-Year Share Buyback Ratio is ranked better than
57.04% of 696 companies
in the Drug Manufacturers industry
Industry Median: -2.2 vs XSWX:EVT: -1.20

Evotec SE (XSWX:EVT) 5-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Evotec SE 5-Year Share Buyback Ratio Related Terms


XSWX:EVT vs ZTS, UTHR, VTRS: 5-Year Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE 5-Year Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's 5-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's 5-Year Share Buyback Ratio falls into.


XSWX:EVT
58GF Score
Evotec SE XSWX:EVT
5-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE 5-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 5-Year Share Buyback Ratio of -1.20 mean?
Evotec SE (XSWX:EVT) has a 5-Year Share Buyback Ratio of -1.20 as of Mar. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #299 out of 696 companies in the Drug Manufacturers industry, placing it in the top 43%.
Is Evotec SE's 5-Year Share Buyback Ratio too high?
Evotec SE's current 5-Year Share Buyback Ratio is -1.20. Based on the distribution chart, Evotec SE ranks #299 out of 696 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Evotec SE has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's 5-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #299 out of 696 companies for 5-Year Share Buyback Ratio. This puts Evotec SE in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 5-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Evotec SE and its competitors. Evotec SE's current 5-Year Share Buyback Ratio is -1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (XSWX:EVT) has a current 5-Year Share Buyback Ratio of -1.20. The stock's GF Value™ is CHF8.56, compared to a current price of CHF4.63 — trading 45.9% below its estimated fair value. The current 5-Year Share Buyback Ratio is -1.20. Evotec SE's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current 5-Year Share Buyback Ratio is -1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (XSWX:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of CHF4.63 is trading 45.9% below its estimated GF Value™ of CHF8.56.

Key valuation signals for XSWX:EVT:

  • 5-Year Share Buyback Ratio: -1.20
  • GF Value™: CHF8.56 vs. price of CHF4.63 (45.9% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
58GF Score

Get the complete analysis for XSWX:EVT

5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF4.63
Price
CHF8.56
GF Value